A claim for surveillance, brought by people who are not sick. Whether it exists at all depends on where you are standing.
Start a conversation with our AI Research Concierge, already scoped to medical monitoring. Pick a starting point, or describe your situation directly.
Medical monitoring addresses the interval between exposure and disease. For contaminants with long latency, someone exposed today may not manifest illness for decades, and by then early detection may no longer be possible. The claim seeks the cost of periodic screening for that population — not compensation for injury, but the expense of watching for one. It is among the most jurisdictionally variable claims in toxic tort: some states permit it without present physical injury, others require injury and thereby foreclose the claim for its intended beneficiaries, and the law is genuinely in motion. The technical showing is more specific than it first appears, because a monitoring programme has to be one the medical literature actually supports.
The elements vary by jurisdiction, but this set recurs across the states that recognise the claim.
Exposure meaningfully greater than background, usually attributable to the defendant.
A demonstrably elevated risk of a serious latent disease as a result.
Screening that actually exists for the disease and detects it earlier than it would otherwise be found.
Surveillance different from what this person would receive anyway — routine care does not count.
That earlier detection changes outcome. Screening for a disease nothing can be done about earlier is harder to justify.
The dividing line between jurisdictions, and frequently dispositive.
How the claim is supported.
Monitoring programmes run for decades across large populations, so the aggregate is substantial even though no individual is claiming injury.
Where present physical injury is required, the claim is unavailable to exactly the people it was designed for. Where it is not, the same facts support it. Recent decisions in New Hampshire and Vermont moved toward recognition; West Virginia has held that a substance in the blood is not itself an injury. Check the current position before building the claim.
Not on its own in every jurisdiction, and that question has become central with PFAS, where serum testing is widely available and elevated levels are common. West Virginia has held that presence of a toxic substance in the blood does not by itself establish a justiciable injury, nor does increased exposure alone. Other courts have been more receptive to biomonitoring evidence as proof of exposure or of subclinical effect. Where the physical injury requirement applies, whether a measurable body burden satisfies it is frequently the argument the whole claim turns on.
That it is drawn from established screening practice rather than designed for the litigation. The protocol should identify a specific disease with elevated risk in this population, use a screening method with demonstrated ability to detect it earlier than ordinary care would, at intervals the clinical literature supports, for a duration matched to the latency. Protocols that propose broad panels of tests with no particular disease in view, or screening for conditions where early detection does not change management, are straightforward to attack on both necessity and cost.
They can complicate them, in ways worth anticipating. Participation in a monitoring programme creates a documented record of exposure and of health status over time, which can support a later injury claim substantially — or undercut one, if the record shows no progression. There are also limitations implications: in some jurisdictions the knowledge that triggers a monitoring claim may start a clock on related claims. It is worth resolving how the two interact before the monitoring claim is filed rather than afterwards.
Both structures exist and courts have differed on which is appropriate. A court-supervised fund pays for actual screening as it is used, which ensures the money goes to monitoring and returns unused amounts. A lump-sum damages award pays each class member directly, which is simpler to administer but does not ensure anyone is monitored. Defendants generally prefer funds, since they limit exposure to actual participation rates, which in practice are frequently well below the class size.
Describe the exposure and the population. We will scope it and connect you with the right expert.